Other Balance Sheet Details

12 Months Ended

Dec. 31, 2023

Other Balance Sheet Details [Abstract]

Inventory, net, consisted of the following:


	December 31,
(in millions)	2023		2022
Raw materials	$	21.5	$	12.0
Work in process	9.7		5.6
Finished goods	12.3		17.5
	43.5		35.1
Less inventory reserves	(5.2)		—
Total inventory, net	$	38.3	$	35.1

Property and equipment, net, consisted of the following:


	December 31,
(in millions)	2023		2022
Tenant improvements	$	38.1	$	37.9
Scientific equipment	79.6		58.8
Computer equipment	25.2		21.5
Furniture and fixtures	10.9		6.7
	153.8		124.9
Less accumulated depreciation	(83.0)		(66.3)
Total property and equipment, net	$	70.8	$	58.6

Accounts payable and accrued liabilities consisted of the following:


	December 31,
(in millions)	2023		2022
Sales rebates and reserves	$	139.3	$	131.9
Accrued employee related costs	86.2		72.8
Current branded prescription drug fee	45.7		27.5
Accrued development costs	44.3		39.1
Current income taxes payable	24.4		9.0
Accounts payable and other accrued liabilities	108.9		67.3
Total accounts payable and accrued liabilities	$	448.8	$	347.6

Other long-term liabilities consisted of the following:


	December 31,
(in millions)	2023		2022
Noncurrent income taxes payable	$	96.0	$	19.8
Noncurrent branded prescription drug fee	10.3		9.9
Total other long-term liabilities	$	106.3	$	29.7

The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.


	December 31,
(in millions)	2023		2022
Cash and cash equivalents	$	251.1	$	262.9
Restricted cash	8.0		7.8
Total cash, cash equivalents and restricted cash	$	259.1	$	270.7